Marathon Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.99M Sell
2,492
-53
-2% -$54.2K 0.61% 47
2026
Q1
$2.34M Sell
2,545
-3
-0.1% -$3.04K 0.53% 49
2025
Q4
$2.74M Sell
2,548
-35
-1% -$33.5K 0.59% 46
2025
Q3
$1.97M Buy
2,583
+7
+0.3% +$5.21K 0.45% 48
2025
Q2
$2.01M Buy
2,576
+450
+21% +$350K 0.51% 49
2025
Q1
$1.76M Sell
2,126
-180
-8% -$150K 0.47% 50
2024
Q4
$1.78M Sell
2,306
-69
-3% -$57.1K 0.44% 48
2024
Q3
$2.1M Sell
2,375
-55
-2% -$49.4K 0.51% 49
2024
Q2
$2.2M Hold
2,430
0.56% 45
2024
Q1
$1.89M Sell
2,430
-130
-5% -$92.5K 0.45% 52
2023
Q4
$1.49M Sell
2,560
-30
-1% -$17.5K 0.38% 62
2023
Q3
$1.39M Hold
2,590
0.35% 62
2023
Q2
$1.21M Sell
2,590
-106
-4% -$44.5K 0.3% 66
2023
Q1
$926K Hold
2,696
0.23% 73
2022
Q4
$986K Sell
2,696
-41
-1% -$14.5K 0.27% 64
2022
Q3
$885K Hold
2,737
0.25% 72
2022
Q2
$887K Buy
+2,737
New +$822K 0.29% 65
2022
Q1
Sell
-2,737
Closed -$756K 131
2021
Q4
$756K Sell
2,737
-951
-26% -$241K 0.18% 81
2021
Q3
$853K Buy
3,688
+961
+35% +$237K 0.19% 73
2021
Q2
$625K Sell
2,727
-100
-4% -$20.1K 0.14% 84
2021
Q1
$528K Hold
2,827
0.14% 88
2020
Q4
$477K Buy
2,827
+30
+1% +$4.48K 0.14% 84
2020
Q3
$414K Sell
2,797
-103
-4% -$15.9K 0.15% 83
2020
Q2
$476K Hold
2,900
0.18% 68
2020
Q1
$402K Hold
2,900
0.18% 66
2019
Q4
$381K Buy
+2,900
New +$336K 0.13% 95

Other funds holding LLY

Marathon Capital Management's LLY Position: Q2 2026 in Review

Marathon Capital Management reduced its Eli Lilly (LLY) stake by 2.1% in Q2 2026, selling an estimated $54.2K and leaving 2,492 shares worth $2.99M. The position accounts for 0.61% of the portfolio, ranked #47.

Marathon Capital Management first reported a position in LLY in Q4 2019 and has held it in 26 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Marathon Capital Management held 2,492 shares of Eli Lilly worth $2.99M as of Q2 2026.
  • Marathon Capital Management sold 53 Eli Lilly shares in Q2 2026, an estimated $54.2K.
  • Eli Lilly made up 0.61% of Marathon Capital Management's portfolio in Q2 2026, its #47 holding.
  • Marathon Capital Management first reported a position in Eli Lilly in Q4 2019 and has held it in 26 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Marathon Capital Management's 13F filing for Q2 2026, filed 22 Jul 2026.